The Next Level: Incorporating Device-Aided Therapies into Parkinson’s Disease Management
The armamentarium of adjunctive and rescue therapies for Parkinson’s disease (PD) has expanded dramatically in recent years. But the availability of so many unique options introduces challenges to determining when patients with more advanced disease may no longer benefit from these options, leading to the questions of how and at what point a change in clinical response should occur. In this activity, Drs Bahroo, Malaty, and Elkurd provide evidence-based insight into best practices incorporating device-aided therapies (DAT) into clinical management of advancing PD.
This activity is intended for movement disorder specialists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the care of patients with PD.
Upon completion of this activity, participants should be better able to:
- Appraise appropriate methods for proactive assessment of both motor and non-motor changes in PD to improve recognition of PD progression/advanced disease and effectively classify patient needs over time.
- Discuss technological advancements of and patient selection for approved device-aided therapies (e.g., carbidopa/levodopa enteral suspension, deep brain stimulation) to determine when and for whom to consider these approaches.
- Distinguish the mechanisms of action and recent Phase 2/3 results for investigational continuous subcutaneous levodopa/carbidopa infusion agents to better understand how to integrate these approaches into routine practice should they garner FDA approval.
- Evaluate the clinical profiles and ongoing Phase 2/3 assessment of continuous subcutaneous apomorphine infusion for PD to determine the potential future role of this strategy.
Laxman Bahroo, DO, FAAN (Chair)
Director, Residency Program
Associate Professor, Department of Neurology
Irene Malaty, MD, FAAN
Medical Director, Parkinson Foundation Center of Excellence at UF
Barbara Padgett Dein Professor of Neurology
University of Florida
Mazen Elkurd, DO
Director, Movement Disorders Center
Baylor University Medical Center
Baylor Scott & White Health
This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For CME questions please contact: email@example.com
Disclosure of Conflict of Interest
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
Planners’ and Managers’ Disclosure
All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.
Laxman Bahroo, DO (Chair)
- Consultant: Amneal, Ipsen, Jazz, Neurocrine, Sunovion, Supernus, Teva
- Speaker Bureau: AbbVie, Acadia, Acorda, Adamas, Amneal, Ipsen, Kyowa Kirin, Neurocrine, Sunovion, Supernus, Teva
- Advisory Board Membership: Acadia, Amneal, Ipsen, Neurocrine, Supernus, Teva
Mazen Elkurd, DO
- Grants/Research Support: Parkinson Foundation
Irene Malaty, MD
- Grants/Research Support: AbbVie, Neuroderm, Revance
- Consultant: AbbVie
- Other Financial or Material Support: Royalties from Robert Rose publishers
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from AbbVie and Supernus.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance